In another study, Daneshmanesh et al. demonstrated that ROR1 expression is significantly higher in CLL patients with progressive versus non-progressive disease and the ROR1 epitopes were used to generate anti-ROR1 mAbs which seem to induce apoptosis, showing complement-dependent toxicity and antibody-dependent cellular toxicity, as rituximab [104]. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.